Entyvio for IBD Shows Promising Safety Results in Long-term Clinical Trial

Entyvio for IBD Shows Promising Safety Results in Long-term Clinical Trial
Takeda Pharmaceuticals recently presented positive five-year results of an eight-year clinical trial (NCT00790933) evaluating the long-term safety of Entyvio (vedolizumab) in patients with active ulcerative colitis and Crohn’s disease, two of the most common inflammatory bowel diseases (IBDs). Interim findings of the GEMINI Phase 3 trial, which began in May 2009 and is expected to be complete

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *